GlassScriptPhysician profile
Abigail Posner
NPI 1609367804
$11,807.28
in general payments reported to CMS, 2019-2025
32 companies · $5,571 in 2025
The $5,571 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $98.34 · 2023: $1,572 · 2024: $4,436 · 2025: $5,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,298.47 |
| Education | $279.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,005.54 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,885.51 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $949.90 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Lilly USA, LLC | $749.79 | 2024-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $742.57 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $727.69 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $622.30 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $427.62 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $389.51 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $300.13 | 2023-2025 | Linzess |
| Ardelyx, INC. | $239.69 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $239.17 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.37 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $170.46 | 2021-2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $132.45 | 2023 | Stelara |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $124.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $111.53 | 2023-2024 | Dificid |
| Celltrion USA INC. | $100.45 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Aimmune Therapeutics, INC. | $97.27 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $88.26 | 2023-2025 | Rebyota |
| Gilead Sciences, INC. | $83.69 | 2024-2025 | |
| Celgene Corporation | $73.92 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $73.29 | 2025 | Iqirvo |
| Organon LLC | $67.04 | 2024-2025 | Hadlima |
| Exact Sciences Corporation | $63.35 | 2024-2025 | Cologuard Collection Kit |
| Sandoz INC. | $46.11 | 2023-2025 | Hyrimoz, Pyzchiva |
| Braintree Laboratories, INC. | $27.21 | 2023-2024 | Suflave, Sutab |
| Daiichi Sankyo INC. | $21.10 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.96 | 2023 | Cyltezo |
| Cumberland Pharmaceuticals, INC. | $17.49 | 2025 | Kristalose |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2024 | Simlandi |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.